COVID-19: Concerns over increased load of residual antibiotics in wastewater
The use of antibiotics during the novel coronavirus disease (COVID-19) and its linkages with antimicrobial resistance (AMR) have earlier been talked about. Antibiotics are being employed — mostly in hospital or intensive care unit settings — to prevent secondary bacterial infections (co-infections) along with the viral infection caused by the SARS-CoV-2 virus that causes COVID-19.
Studies showed while the prevalence of bacterial infections was low in COVID-19 patients, a majority of them were administered with antibiotics, including broad spectrum ones. This was often done as part of empiric therapy, in the absence of appropriate bacterial characterisation or antibiotic susceptibility testing.
In parallel, there were emerging concerns over implications of such high levels of antibiotic use on the environment.
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.